If starting at **9–14 Years**

**2** DOSES

**If starting at 15–45 years**

or with compromised immune system at any age

**3** DOSES

---

Footnotes:

1. Routinely recommended at ages 11-12 years. Vaccination as early as age 9 years is an option for all children and recommended for those with a history of sexual abuse or assault. Catch-up vaccination recommended for all adolescents over 13 years.

2. Minimum acceptable interval is 5 months.

3. Includes conditions that reduce cell-mediated or humoral immunity, such as B lymphocyte antibody deficiencies, T lymphocyte complete or partial defects, HIV infection, malignant neoplasms, transplantation, autoimmune disease, or immunosuppressive therapy. The recommendation for a 3 dose schedule does not apply to persons <15 years with asplenia, asthma, chronic granulomatous disease, chronic liver disease, chronic lung disease, chronic renal disease, central nervous system anatomic barrier defects (e.g., cochlear implant), complement deficiency, diabetes, heart disease, or sickle cell disease.

4. Recommended for all persons through age 26. Shared clinical decision-making is recommended for some adults aged 27-45 years who are not adequately vaccinated.

5. Minimum acceptable interval is 4 weeks between the 1st and 2nd dose and 12 weeks between the 2nd and 3rd dose.

Additional Notes:

- If the vaccination schedule is interrupted, the series does not need to be restarted.
- The number of recommended doses is based on age at administration of the first dose.
- HPV9 may be used to continue or complete a vaccination series started with 4vHPV or 2vHPV.